BONK, INC. quarterly report, Q1 FY2024

Business context and reporting period

Important identity mismatch: The request identifies BONK, INC., but the supplied Form 10-Q is for Safety Shot, Inc. (Nasdaq: SHOT; warrants: SHOTW), for the quarter ended March 31, 2024. This summary reflects the supplied filing, not BONK, INC.

Safety Shot sells consumer wellness products and launched its Safety Shot dietary supplement in December 2023. The company says it is focusing on commercializing that product, sold primarily through e-commerce, while pursuing retail distribution and other product development.

Financial results and liquidity

At March 31, 2024, cash was $2.05 million, marketable securities $243,000, current assets $4.34 million, current liabilities $3.40 million, and working capital $947,504. Total assets were $9.21 million and total liabilities $3.64 million. Convertible notes were reported at $1.57 million, including accrued interest; the SBA loan balance was $49,289. Lease liabilities totaled approximately $473,000.

Material changes versus the prior comparable period

• Revenue increased to $171,000 from $35,000 following the product launch, but cost of sales exceeded revenue. The company attributes much of the cost increase to launch costs and a $1.745 million inventory write-down related to rebranding.
• Operating expenses rose substantially, including $8.09 million of stock-based compensation, $2.38 million of legal and professional expenses, and $1.45 million of marketing expenses.
• Operating cash use increased to $6.39 million. Cash declined by $1.79 million during the quarter, partly offset by $3.79 million of proceeds from warrant exercises and $809,000 from selling marketable securities.
• Common shares outstanding increased from 45.63 million at year-end to 49.22 million at quarter-end. The company also granted substantial options during the quarter.

Outlook, risks, contingencies, and unusual items

• Going concern: The company says its accumulated deficit, operating cash use, and limited cash and working capital raise substantial doubt about its ability to continue as a going concern. It expects significant further spending. No quantified financial guidance is provided.
• Financing after quarter-end: The company reports that it raised $5.0 million in a private placement after March 31, 2024, through issuance of 2,369,668 shares at market price.
• Convertible notes: The remaining principal balance was $1.07 million; the due date was extended to June 30, 2024. The balance sheet reports convertible notes of $1.57 million, including accrued amounts.
• Legal matters: Several warrant-related lawsuits seek damages, shares, or specific performance. Claims described include at least $2 million sought by Intracoastal; at least $750,000 in compensatory and $600,000 in liquidated damages sought by Sabby in one case; approximately $380,000 sought by 3i; and $3 million in compensatory plus an estimated $4 million in liquidated damages sought by Bigger Capital. The company says it intends to defend the claims and does not expect material adverse effects. A separate Coachella dispute was settled, including a permanent injunction and a payment the company says is not material. The company also obtained a default judgment against Capybara Research and an individual, and reached a retraction settlement with Benzinga.
• Controls: The filing contains conflicting statements: one says disclosure controls were effective, while a later assessment says they were ineffective. Management cites a small team and plans to expand the team and internal-control framework; it also describes remediation efforts.
• Product and regulatory risks: Safety Shot is marketed as a dietary supplement, not an FDA-approved drug. The filing discusses applicable supplement, labeling, advertising, and other regulations. Commercial success, product claims, retailer expansion, and customer acceptance remain uncertain.

Key facts investors should verify

• Confirm the intended issuer: the supplied filing is Safety Shot, Inc. (SHOT), not BONK, INC.
• Review the going-concern disclosure and assess whether the post-quarter $5 million financing is sufficient relative to cash burn and planned spending.
• Verify the composition of cost of sales, including the $1.745 million inventory write-down, and whether gross margins improve after launch and rebranding costs.
• Assess potential dilution from shares issued, outstanding warrants, and the large option grants.
• Track the status and potential financial impact of the warrant-related lawsuits and confirm the terms and accounting for the Coachella settlement.
• Reconcile the filing’s conflicting disclosure-controls conclusions and its differing descriptions of stock-based compensation and note balances.